Published in Int J Mol Sci on August 19, 2015
Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients. J Immunol Res (2016) 0.76
Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (Baltimore) (2016) 0.75
Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus. PLoS One (2016) 0.75
Toward ending hepatitis C virus infection: What are the next steps? CMAJ (2017) 0.75
Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. Dtsch Arztebl Int (2017) 0.75
Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals. Indian J Gastroenterol (2017) 0.75
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst (2009) 6.21
EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol (2015) 5.75
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2013) 4.46
Overweight, obesity, and cancer risk. Lancet Oncol (2002) 4.44
Carcinogenicity of alcoholic beverages. Lancet Oncol (2007) 3.98
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology (2007) 3.73
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology (2002) 3.59
Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med (2008) 3.54
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology (2014) 3.30
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology (2015) 3.27
Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med (2005) 3.18
Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol (2013) 3.09
Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut (2005) 2.90
Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol (2012) 2.89
Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med (2000) 2.67
Tobacco smoking and cancer: a meta-analysis. Int J Cancer (2008) 2.64
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol (2010) 2.43
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology (2013) 2.36
A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis (2013) 2.02
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology (2008) 1.95
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol (2010) 1.93
A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol (2009) 1.86
A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther (2006) 1.48
Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev (2006) 1.47
The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol (2008) 1.44
Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med (2008) 1.42
Heavy smoking and liver. World J Gastroenterol (2006) 1.33
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology (2012) 1.29
Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control (2003) 1.23
Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol (2000) 1.19
Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut (2004) 1.17
Smoking and liver cancer in China: case-control comparison of 36,000 liver cancer deaths vs. 17,000 cirrhosis deaths. Int J Cancer (2003) 1.15
Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol (2014) 1.14
Smoking as an independent risk factor for hepatocellular carcinoma: the Singapore Chinese Health Study. Br J Cancer (2011) 1.10
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1997) 1.09
Mechanism of ethanol induced hepatic injury. Pharmacol Ther (1990) 1.09
Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol (2005) 1.07
A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother (2012) 1.01
Alcohol-related diseases and carcinogenesis. Cancer Res (1979) 1.00
Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol (2007) 0.96
Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. Liver Int (2004) 0.94
Is hepatitis C virus carcinogenic? Gastroenterology (2012) 0.93
Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther (2015) 0.85